Core Points - XORTX Therapeutics Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of US$1.00 per share, now having until April 13, 2026 to meet this requirement [2][3] - If the company's common shares close at or above $1 for at least 10 consecutive business days during the extension period, Nasdaq will notify the company of compliance [3] - Failure to demonstrate compliance by the deadline may result in delisting, although the company can appeal this decision [3] Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease, with three advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [5] - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [5] - XORTX is committed to improving the quality of life for individuals suffering from gout and other significant diseases [5]